The 104 per cent US tariff on Chinese chemical imports is set to raise production costs, strain supply chains, and trigger inflation across sectors like pharmaceuticals and agriculture.
With limited alternatives, US firms would face delays, higher compliance costs, and reduced global competitiveness, while reshoring remains a long-term, costly solution.